Related Experiment Video
Updated: Oct 30, 2025
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
A patent review of MALT1 inhibitors (2013-present)
Isabel Hamp1,2, Thomas J O'Neill3, Oliver Plettenburg1,2
1Institute for Medicinal Chemistry, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
Introduction:
MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulatory target for the treatment of autoimmune/inflammatory diseases. Further, chronic MALT1 protease activation drives survival of lymphomas, suggesting that MALT1 is a suitable drug target for lymphoid malignancies. Recent studies have indicated that MALT1 inhibition impairs immune suppressive function of regulatory T cells in the tumor microenvironment, suggesting that MALT1 inhibitors may boost anti-tumor immunity in the treatment of solid cancers.
Areas Covered:
This review summarizes the literature on MALT1 patents and applications. We discuss the potential therapeutic uses for MALT1 inhibitors based on patents and scientific literature.
Expert Opinion:
There has been a steep increase in MALT1 inhibitor patents. Compounds with high selectivity and good bioavailability have been developed. An allosteric binding pocket is the preferred site for potent and selective MALT1 targeting. MALT1 inhibitors have moved to early clinical trials, but toxicological studies indicate that long-term MALT1 inhibition can disrupt immune homeostasis and lead to autoimmunity. Even though this poses risks, preventing immune suppression may favor the use of MALT1 inhibitors in cancer immunotherapies.
Insights
MALT1 inhibitors are emerging as promising treatments for autoimmune diseases and cancers. While clinical trials show potential, long-term use risks immune disruption, necessitating careful therapeutic strategies for MALT1 targeting.
Area of Science:
- Biochemistry
- Immunology
- Drug Discovery
Background:
- Mucosa-Associated Lymphoid Tissue 1 (MALT1) is a unique human paracaspase crucial for immune responses.
- Dysregulated MALT1 activity is implicated in autoimmune/inflammatory diseases and lymphoid malignancies.
- MALT1 inhibition shows potential in modulating regulatory T cells for anti-tumor immunity.
Purpose of the Study:
- To review MALT1 inhibitor patents and applications.
- To discuss potential therapeutic applications of MALT1 inhibitors based on scientific literature.
Main Methods:
- Literature review of MALT1 patents.
- Analysis of scientific publications on MALT1 inhibitors.
Main Results:
- Significant increase in MALT1 inhibitor patents, with compounds demonstrating high selectivity and bioavailability.
- Allosteric binding sites are favored for potent and selective MALT1 inhibition.
- MALT1 inhibitors are progressing to early clinical trials.
Conclusions:
- Long-term MALT1 inhibition may disrupt immune homeostasis and cause autoimmunity.
- Despite risks, MALT1 inhibitors hold promise for cancer immunotherapy by preventing immune suppression.
